Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please stop comparing CELG to PMCB by price per share
Market cap of CELG is only 3 Billion USD
If PMCB had the same market cap price would ONLY be $3.50 per share!
NEWS!!!!!!
LAGUNA HILLS, Calif., Jan. 10, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the second article in a series of Q&A articles that will be conducted with some of the key team members of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
http://ir.pharmacytebiotech.com/press-releases/detail/127
This article, which comes one week before PharmaCyte’s pre-IND meeting with the FDA, is with Dr. Manuel Hidalgo, the Principal Investigator of PharmaCyte’s clinical trial in LAPC. Dr. Hidalgo is Chief of the Division of Hematology/Oncology and the Director of the Rosenberg Clinical Cancer Center of the Beth Israel Deaconess Medical Center in Boston, Massachusetts. He is also a Member of the Faculty of Medicine of the Harvard Medical School and Co-Director of the international Pancreatic Cancer Research Program.
What are your thoughts on PharmaCyte's therapy for LAPC and its technology Cell in a Box®?
Dr. Manuel Hidalgo: “Locally advanced inoperable pancreas adenocarcinoma (pancreatic cancer or PDAC) is a significant health issue. About 30% of patients with pancreatic cancer present with disease that is localized but cannot be resected in full. These patients are now managed with chemotherapy and radiation therapy with poor results. One of the reasons why these results are poor is because the concentration of chemotherapy that reaches the pancreas tumor may be too low to exert its therapeutic effects. However, Cell in a Box® is a new innovative technology that may result in higher concentrations of chemotherapy at the site of the pancreas cancer. The way this is achieved is by encapsulating living cells that have the capacity to enzymatically activate a drug called ifosfamide in the pancreas tumor itself. By doing so, the concentration of active drug in the tumor bed increases which likely results in better efficacy while there is less systemic exposure to the active drug with the corresponding decrease in toxicity.”
What did you see in the early data from the 2 previous clinical trials that gives you confidence with PharmaCyte’s therapy heading into the upcoming clinical trial?
Dr. Manuel Hidalgo: “The data is promising and suggests this approach should be further tested. In addition to early evidence of efficacy, the study showed minimal toxicity, consistent with decreased systemic exposure to the active drug and improvement in quality of life. These are very important observations. However, the previous studies were small, and we need additional data.”
As the Principle Investigator for the upcoming clinical trial, why is it important for you to be involved with this clinical trial?
Dr. Manuel Hidalgo: “As investigators involved in PDAC research, we are always looking for new, safe strategies to improve patient outcome. In this disease, we really need innovation. We need new approaches and strategies, and Cell in a Box® is indeed a new strategy. I am very excited because of the novelty of the approach. I am also very glad to be working with a terrific group of people both on the PharmaCyte side and in the investigators team.”
You have been a part of so many clinical trials. What have you learned or experienced from those previous clinical trials that you can bring to this clinical trial?
Dr. Manuel Hidalgo: “When conducting a clinical trial, the most important thing is to preserve the safety of the subjects and integrity of the data. To that end, it is critical to meticulously select the subjects and follow the protocol. As overall Principal Investigator, I will be working closely with other investigators and the sponsor to make sure the study is conducted according to good clinical practice and other pertinent regulations. Of course, in the day to day, there are always special situations. Here is where the expertise of the investigators team plays an important role. The two key features are to properly document every observation and to communicate and ask any question that may emerge.”
As a long-time friend and colleague of Dr. Von Hoff and relatively new friend and colleague of Dr. Löhr, what are your thoughts about being teamed up with them for this upcoming clinical trial?
Dr. Manuel Hidalgo: “I am naturally very excited with the opportunity to work with such terrific doctors and investigators. The conduct of the study is a team effort, and having such high caliber investigators on the team provides us with the expertise needed for the success of this clinical trial.”
What experiences can you draw on from the Abraxane® clinical trial that you were involved in with Dr. Von Hoff that you can bring to PharmaCyte’s clinical trial?
Dr. Manuel Hidalgo: “Through a series of clinical and preclinical studies led by Dr. Von Hoff, myself and many other excellent investigators, we showed that Abraxane® is effective in pancreatic cancer leading to its approval. The development of this drug provided us with a firsthand experience on how to take a new agent from concept to approval. We will now apply all of this knowledge and expertise to develop Cell in a Box® for pancreas cancer treatment. These are obviously very different technologies, but the principles of conducting a high quality step-wise development plan are similar.”
For those who aren't familiar with the clinical trial process and the development of a therapy for pancreatic cancer, why is it important to have an experienced team surrounding PharmaCyte's technology heading into its clinical trial?
Dr. Manuel Hidalgo: “I cannot emphasize enough how important having an experienced team is to conducting any clinical trial, but even more a trial with a new technology like Cell in a Box®. Elements of an experienced team range from proper patient selection to the delivery of the treatment and monitoring safety and efficacy. Each one of these elements, just to name a few, requires careful attention to details, proper documentation and communication. As this is a new technology and is a non-conventional one, these details become even more important. This is like a performance. The sheet music (protocol) is important but the conductor (investigator) and the orchestra (research team) are also critical.”
What do you think about going head to head with gemcitabine as the comparator arm in PharmaCyte’s clinical trial?
Dr. Manuel Hidalgo: “While patients with locally advanced pancreatic cancer are managed in many different ways around the globe, one can argue that the data from the LAP007 trial shows that gemcitabine alone is as good as gemcitabine combined with radiation therapy. Based on these data, from a regulatory perspective, we think gemcitabine alone is the accepted standard of care and have written the protocol that way.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.
In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical studies and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be
That's what I meant. All I said was that we are waiting on the next step. That next step is the pre IND FDA meeting.
One step at a time to our goal of trials.
That's all I meant. Pretty trivial.
All you need to know is that 2017 is going to be monumental year. We are very likely to start trials this year. Possibly in the beginning of the year here. All we are waiting on right now is the FDA meeting results which is scheduled for the 17th of January. The outcome of the meeting will determine the beginning of the trial.
is this the last time we will see .12?
not worried... even if dropped back to .08 I would still hold
One thing that really helped us about a month ago is that when it reached .08 a lot of people shorted the stock and when we broke through that barrier everyone started to cover.
It's what pushed us to .155
I say let them short! The bigger the kaboom!
Today will bea rebound day for sure... most days we start off with lots of buys but end up going down toward the day.. I think there will be some panic sells that have been instigated by the MM crew... however it will go back with a reverse pattern by the end of the day
nope... still up and hope it stays up!
the thing is though
there is nothing to sell...
Don't be surprised if those shares were bought just to be dropped later...
to make it look like something else
0.1399 they're holding it down for sure... .0009 spread atm
Possible PPS movers?
Yeah I am actually surprised myself, but I really think there something else going on here.
Someone could have loaded up on shares just to drop them during the release of news?
Possibility?
MM's definitely holding it down
down today up tomorrow
was hoping we would have an amazing start for the new year with some news, but looks like we are going to have to wait some more!
.0002
spread at .0005
buying pressure... its going to pop today .16 for sure
today we will break .17
call me crazy, but the first day of 2017 will start off with a bang...
hope you bought your shares
Cheers to a great comeback! And cheers to a great year!!
WOW
We pretty much closed where we started!! That is incredible!
I feel so so bad for everyone who got scared and jumped the boat.
(Sigh)
SMH
When we come back Tuesday I think PMCB is going to rally.
I've always believed in PMCB!
Bingo got it with ctrl-f
thanks so much
Go PMCB
That's a bit much for me right now, but looks well detailed. Eyes are really heavy. If there was a direct comparison that was easy to see it would really help.
Well, that's very reassuring to hear! If anyone else would like to chime in with some comparisons or more information/facts, I'm all ears! Please, reply so I get your message. I am off to bed now as it's near midnight where I am at.
Happy new year to everyone! Look forward to 2017 being an awesome year!
(Actually, ViaCyte is funded by Johnson &Johnson, but I wouldn't be surprised if they were behind the MM's keeping the price down, or funding the bizarre Y*hoo message board propaganda)
Reason I ask is because I tried to find more information, but couldn't see anything on their website in regards to them being micro/macro or their size.
All I know is that they require a surgical procedure, so you may be right. If that IS the case then CIAB would be far superior and possibly less painful (if there is discomfort or pain associated with the procedure).
Interesting, how do know you this?
However keep in mind, that while this technology is extremely promising, there are competitors out there with similar technology.
A company called ViaCyte... eerily/strangely similar to PharmaCyte is already in clinicals for type 1 and type 2 diabetes using cell encapsulation. They had their IND meeting in 2014 and are currently in phase 1/2.
Management is currently focusing on pancreatic cancer because there is an urgent unmet need. Considering that we have the best of the best on board, I would say PMCB has a high likelihood of fulfilling that need.
Once that is out of the way, diabetes will sure follow, but it's hard to say if another encapsulation technology will have already entered the market.
I know when you look at a stock you have to think rationally. There is always risk involved... and competition, but I believe PMCB has got what it takes.
If you really want you can read the book by Dr. Brandtner who co-developed the cells. Her name is on the patents to this technology.
http://ebooks.benthamscience.com/book/9781608057207/
I can start by saying we have world renown oncologists on the team here at PMCB including Dr. Daniel Von Hoff who is considered the world's leading expert on pancreatic cancer.
He has taken many drugs through the FDA approval process. That alone should tell you a lot of things.
New management has assembled a consortium of oncologists like Von Hoff to bring CIAB to the market.
They've taken care of CGMP certification for facilities in Thailand to be able to manufacture CIAB.
Now they've gotten us to the door of the FDA.
Management is well experienced. I'm sure you'll find that out once you check them out for yourself. A lot of other members here could link you to some good information.
Everything on the intro to this board is nice starting point if you haven't skimmed over it yet.
So great! Love the big vision! Love the energy!
This guy sees it!!!
Great to have you on board! Pun intended ;)
I think once you do your own research you will become a believer and hard LONG.
definitely possible, but we shall see
I feel bad for all the people selling now.. sheesh
Dollar volume at about 250k USD for the end of the day.
Compare that with about 3,000k USD just not too long ago.
People have bought.. dust has settled.
we're all waiting now patiently...
They are keeping it where it's at and knocking out momentum. I am beginning to believe that each morning there is a pump to see if they can shake people out.
The big asks are there to scare people from buying more shares. They look intimidating for a reason.
Despite the huge volume on the ask the price is relatively stable. They keep trying to walk the price down, but it isn't happening.
They succeed a little bit, but PMCB is too strong right now to drastically drop in price. They can still put a ceiling on how high it's going to go, though, as we are witnessing.
First trading day of the year we are probably going to get hit with some news. Tomorrow should be a rally to get in on the action before the new year hits.
Say goodbye to 2016.
These prices we will never see again.
Charts are really poor for predicting a stock like this. They can give us whatever figures they want, but a chart is not going to predict a buy out or the trial results.
Hahaha that's great can't wait to be on that island...
I am pretty sure the island shape will look like this: $
350k shares on the ask.. If I had the money
Someone else would have to answer that, but it's always a possibility. There are a lot of shares in circulation, but the price may just get there on it's own, especially if someone decides to go for a buyout right after trials end.
Then there would be no reason to do a reverse split.
In my opinion I don't think it would be necessary. I think they timed everything just right.